Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology - Netherlands
doi 10.1016/j.molonc.2016.05.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

HLA Class II Haplotypes Predict Favorable Outcomes for Patients With Metastatic RCC

Der Urologe
Urology
2004English

HLA Class II Polymorphisms and Susceptibility to Recurrent Respiratory Papillomatosis

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2003English

HLA Class-I and Class-Ii Restricted Neoantigen Loads Predict Overall Survival in Breast Cancer

OncoImmunology
OncologyAllergyImmunology
2020English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Single-Institution Retrospective Review of Patients With Recurrent Glioblastoma Treated With Bevacizumab in Clinical Practice

Health Science Reports
2019English

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Bevacizumab and Fotemustine for Recurrent Glioblastoma: A Phase II Study of AINO (Italian Association of Neuro-Oncology)

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy